Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab pilot study in cutaneous lupus erythematosus
2008-003833-25Phase 2Terminated
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efalizumab in cutaneous lupus erythematosus (CLE), discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and 1 more, sponsored by Universitätsklinikum Schleswig-Holstein. Started Oct 2008; status: terminated.
02
Drugs
efalizumab
03
Conditions
cutaneous lupus erythematosus (CLE)discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2008-003833-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003833-25.